Klaus Urbahns

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Richard D. Caldwell, Hui Qiu, Ben Askew et al. · Journal of Medicinal Chemistry · 2019 · 136 citations · Full text

Novel Therapy, Medicine, Tyrosine Kinase +14

Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening

Paul Czodrowski, Aurélie Mallinger, Dirk Wienke et al. · Journal of Medicinal Chemistry · 2016 · 106 citations · Full text

Drug Target, Structure-based Optimization, Excellent Kinase Selectivity +20

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases

Paul A. Clarke, Maria-Jesus Ortiz-Ruiz, Robert te Poele et al. · eLife · 2016 · 92 citations · Full text

Therapeutic Potential, Immunology, Molecular Biology +17

4-Phenyl-4H-pyrans as IKCa channel blockers

Klaus Urbahns, Ervin Horváth, Johannes-Peter Stasch et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 73 citations

Ikca Channel Blockers, Heterocycle Chemistry, Linear Chain Compound

Selective intermediate‐/small‐conductance calcium‐activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma

Frank Mauler, Volker Hinz, Ervin Horváth et al. · European Journal of Neuroscience · 2004 · 69 citations

Traumatic Brain Injury, Neuromodulation Therapies, Pharmacotherapy +27